Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 11;55(10):1953-1966.e10.
doi: 10.1016/j.immuni.2022.09.004. Epub 2022 Sep 28.

High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity

Affiliations
Free article

High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity

Rodrigo Vazquez-Lombardi et al. Immunity. .
Free article

Abstract

A major challenge in adoptive T cell immunotherapy is the discovery of natural T cell receptors (TCRs) with high activity and specificity to tumor antigens. Engineering synthetic TCRs for increased tumor antigen recognition is complicated by the risk of introducing cross-reactivity and by the poor correlation that can exist between binding affinity and activity of TCRs in response to antigen (peptide-MHC). Here, we developed TCR-Engine, a method combining genome editing, computational design, and deep sequencing to engineer the functional activity and specificity of TCRs on the surface of a human T cell line at high throughput. We applied TCR-Engine to successfully engineer synthetic TCRs for increased potency and specificity to a clinically relevant tumor-associated antigen (MAGE-A3) and validated their translational potential through multiple in vitro and in vivo assessments of safety and efficacy. Thus, TCR-Engine represents a valuable technology for engineering of safe and potent synthetic TCRs for immunotherapy applications.

Keywords: T cell receptor; TCR; deep sequencing; immunotherapy; protein engineering.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests ETH Zurich has filed for patent protection on the technology and sequences described herein, and R.V.-L., J.S.J., and S.T.R. are named as co-inventors on this patent (WO2021074249A1). R.V.-L and S.T.R. are co-founders and hold shares of Engimmune Therapeutics AG. S.T.R. may hold shares of Alloy Therapeutics. S.T.R. is on the scientific advisory board of Engimmune Therapeutics and Alloy Therapeutics.

Publication types

LinkOut - more resources